WHO Prequalification of Diagnostics Programme
PUBLIC REPORT
Product: Abbott RealTi m e HIV-1 Qualitative (Manual)
Number: PQDx 0151-027-00
Abstract
The Abbott RealTi m e HIV-1 Qualitative (Manual)with product code 4N66-90, manufactured by Abbott Molecular Inc., 1300 East Touhy Avenue, Des Plaines, IL 60018, United States of America, CE-marked regulatory version, was accepted for the WHO list of prequalified diagnostics and was listed on 30 May 2013. This version of the product is intended to be used in conjunction with the following instruments/reagents: 9K14-02, 9K15-01, 4N66-80, 4N66-01, 6K12-24 and 4N66-66 (optional).
The Abbott RealTi m e HIV-1 Qualitative is an in vitro amplification assay for the qualitative detection of Human Immunodeficiency Virus Type 1 (HIV-1) nucleic acids from human plasma and dried blood spots (DBS). The Abbott RealTi m e HIV-1 Qualitative is intended to be used as an aid in the diagnosis of HIV-1 infection in pediatric and adult subjects. The Abbott RealTi m e HIV-1 Qualitative is not intende
d to be used as a donor screening test for HIV-1.
The Abbott RealTi m e HIV-1 Qualitative assay detects HIV-1 nucleic acids by using Polymerase Chain Reaction (PCR) technology with homogeneous real-time fluorescent detection. Partially double-stranded fluorescent probe design allows detection of diverse HIV-1 groups and subtypes. The assay uses either human plasma or DBS specimen type and reports a qualitative result.
In order to perform the assay, the following components are required: Instrumentation:
Abbott m2000rt Instrument 9K15-01
Reagents:
•Abbott m Sample Preparation System DNA 6K12-24工装制作 •Abbott RealTi m e HIV-1 Qualitative Amplification Reagent Kit 4N66-90
•Abbott RealTi m e HIV-1 Qualitative Control Kit 4N66-80
Software:
•Abbott RealTi m e HIV‑1 Qualitative m2000 System Combined Application CD‑ROM 4N66-01 or higher
Optional:
• Abbott RealTi m e HIV-1 UNG Protocol 4N66-66
Consumables required:
• Abbott m2000rt Optical Calibration kit 4J71-93
• Calibrated Pipettes capable of delivering 20‑1000 μL
手摇三轮车
• Aerosol Barrier Pipette Tips for 20-1000 μL Pipettes
• 5 mL Reaction Vessels (List No. 4J71-20)
• 1.5 mL screw top microfuge tubes and caps (List No. 04J71-50 or equivalent)
• Magnetic stands for 5 mL Reaction Vessels
• Non-magnetic stands for 5 mL Reaction Vessels
• Magnetic stands for 1.5 mL tubes
• Non-magnetic stands for 1.5 mL tubes
• Dry heating block for 5 mL Reaction Vessels (capable of achieving 50°C)
• Dry heating block for 1.5 mL tubes (capable of achieving 75°C)
• Thermometer
• Timer
• Vortex Mixer
• USP Grade 190-200 Proof Ethanol (95%-100% Ethanol). Do not use ethanol that contains denaturants
• Liquid Container for waste (no bleach should be allowed to contact liquid waste).
• Abbott Optical Adhesive Covers (List No. 4J71-75)
• Abbott Adhesive Cover Applicator (List No. 9K32-01)
• Abbott Splash-Free Support Base (List No. 9K31-01)水过滤板
• Centrifuge capable of 2000g
• Centrifuge capable of 5,000g (for centrifuging the Abbott 96-Well Optical Reaction Plate) • Repeat pipettor capable of delivering 40-50 μL volumes (optional)
• Sterile repeat pipettor tips capable of del ivering 40-50 μL volumes (optional)
• Disposable transfer pipettes (optional)
• 96 well polypropylene plate (optional)
• Bulk m LysisDNA Buffer (List No. 2N77-01) (for DBS processing only)
• 50 mL Tubes (NUNC or equivalent) (optional) (for DBS processing only)
• Eppendorf PCR Cooler
• Abbott 96-Well Optical Reaction Plate (List no. 4J71-70)
• Single-use Rnase/Dnase-free tube or container
Storage:
The Abbott RealTi m e HIV-1 Qualitative Control Kit must be stored at -10°C or colder.
The Abbott RealTi m e HIV-1 Qualitative Amplification Reagent Kit must be stored at -10°C or colder.
The Abbott m Sample Preparation System DNA must be stored at 15-30°C.
The Uracil-N-glycosylase (UNG) required for the Abbott RealTi m e HIV-1 UNG Protocol 4N66-66 must be stored at -15 to -25°C.
Maximum shelf-life upon manufacture:
Abbott RealTi m e HIV-1 Qualitative Amplification Reagent Kit 4N66-90:ad8009
Abbott RealTi m e HIV-1 Internal Control 2G31Y: 18 months.
Thermostable rTth Polymerase Enzyme 56685: per control date on vendor certificate of analysis.
HIV-1 Oligonucleotide Reagent 2G31L : 18 months.
Activation Reagent 93591: 18 months.
Abbott RealTi m e HIV-1 Qualitative Control Kit 4N66-80:
Negative Control 2G31Z 18 months.
High Positive Control 2G31X 18 months.
The Abbott m Sample Preparation System DNA: 18 months.
Summary of prequalification status for Abbott RealTi m e HIV-1 Qualitative
(Manual)
MR: Meets Requirements
NA: Not Applicable
FT: Fast-Tracked
The Abbott RealTi m e HIV-1 Qualitative (Manual) was accepted for the WHO list of prequalified diagnostics on the basis of data submitted and publicly available information.
电光源设备Background information
Abbott Molecular Inc. submitted an application for prequalification of Abbott RealTi m e HIV-1 Qualitative (Manual). Based on the established prioritization criteria, Abbott RealTi m e HIV-1 Qualitative (Manual) was given priority for prequalification.
Product dossier assessment
表面热电阻
Abbott Molecular Inc. submitted a product dossier for Abbott RealTi m e HIV-1 Qualitative (Manual) as per the Instructions for compilation of a product dossier (PQDx_018 v1). The information submitted in the product dossier was reviewed by WHO staff and external experts (assessors) appointed by WHO in accordance with the internal report on the screening and assessment of a product dossier (PQDx_009 v2). Based on the product dossier screening and assessment findings, a recommendation was made to accept the product dossier for Abbott RealTi m e HIV-1 Qualitative (Manual) for prequalification. Commitments for prequalification:
The manufacturer has amended and submitted additional documentation as per the product dossier assessment findings. No further amendments are required. Manufacturing site inspection
A comprehensive inspection was performed at the site of manufacture of the Abbott RealTi m e HIV-1 Qualitative (Manual) (1300 East Touhy Avenue, 60018 Des Plaines, IL, USA) within the context of the prequalification assessment of the Abbott RealTi m e HIV-1 (m2000sp) on 29 June-1 July 2011 as per the Information for manufacturers on prequalification inspection procedures for the sites of manufacture of diagnostics (PQDx_014 v1). The inspection found that the manufacturer had an acceptable quality management system and good manufacturing practices in place that ensured the consistent manufacture of a product of good quality. The manufacturer's responses to the nonconformities found at the time of the inspection were accepted on 29 September 2011. Commitments for prequalification:
The same commitments made for prequalification of the Abbott RealTi m e HIV-1 (m2000sp) apply:
1. Risk Management Files will be updated to include risk analysis for end users in
resource limited and environmentally challenging regions to which the product is
distributed. This will apply to the Abbott RealTi m e HIV-1 (m2000sp) product as well as to the related products.
2. Abbott Molecular Inc. has committed to work towards improving communication
(e.g. customer feedback mechanisms, tailored training, labeling) for users in resource
limited regions where communication may be problematic.
Laboratory evaluation
Given the regulatory version of the product submitted for prequalification and the quality of the data submitted as part of the product dossier to support the claims for its intended use, the Abbott RealTi m e HIV-1 Qualitative (Manual) assay has been found eligible to undergo the WHO fast track procedure. Subsequently, the product will not be required to undergo a laboratory evaluation.
豫公网安备41160202000603
站长QQ:729038198
关于我们
投诉建议